Forbes Recognizes #MedTech as “Venture Capital’s Most Promising Frontier”
By Integrate Ed • October 31, 2025 1:28 pm
“MedTech may well become the next defining chapter in venture capital,” the Forbes article states as it cites Mckinsey and Company. The article says the cost to commercialization a MedTech product concept to is 10x to 100x lower than the amounts needed for biotech! Also, MedTech companies tend to exit in 10 to 12 years as compared to biotech’s much longer horizon, but the article’s author, Melissa Houston, believes that can be shortened to five years post-investment with the proper operational discipline and strategic focus.
The article goes on to highlight the “Founder Factor”, which is that an overlooked aspect of MedTech investing is the founder(s) themselves. Many – like Integrate Ed’s founder – are subject matter experts building “first-in-class” technologies without also having previous experience running a business. The main interviewee of the article, Judyanna Yu, Managing Partner of Onesix8 Venture Capital, claims: “MedTech founders face a steep learning curve but when they’re paired with the right operational support, the results can be remarkable.”
We couldn’t agree more!